Abstract

microRNA-9 (“miR-9”), upregulated in human gastric cancer (GC) tissues, targets LMX1A (LIM homeobox transcription factor 1α) to promote GC cell progression. The underlying mechanism of miR-9 upregulation in GC is still unknown. Through searching multiple long non-coding RNA (LncRNA) databases, we here discovered that the long non-coding RNA LINC00682 (long intergenic non-protein coding RNA 682) putatively targets miR-9. We show that ectopic overexpression of LINC00682 induced miR-9 downregulation but LMX1A upregulation, inhibiting AGS cell survival, proliferation, migration and invasion. Significant apoptosis activation was detected in LINC00682-overexpressed AGS cells. Contrarily, LINC00682 knockdown induced miR-9 upregulation but LMX1A downregulation, promoting AGS cell survival, proliferation, migration and invasion. In the primary human GC cells, forced LINC00682 overexpression similarly induced miR-9 downregulation and LMX1A upregulation, causing proliferation inhibition and apoptosis activation. Significantly, restoring miR-9 expression by a lentiviral construct reversed LINC00682-induced actions in GC cells. Furthermore, LINC00682 was ineffective in LMX1A KO AGS cells. Importantly, LINC00682 expression levels are significantly downregulated in human GC tissues. We conclude that LINC00682 inhibits GC cell progression via targeting miR-9-LMX1A signaling axis.

Highlights

  • Gastric cancer (GC) accounts for over 10% of new cancer cases each year [1,2,3]

  • We hypothesized that miR-9 upregulation in gastric cancer (GC) tissues could possibly be due to downregulation of certain long non-coding RNA (LncRNA)

  • The LncRNAs were further verified by searching other LncRNA/miRNA databases (StarBase and miRbase)

Read more

Summary

Introduction

Gastric cancer (GC) accounts for over 10% of new cancer cases each year [1,2,3]. It is one leading cause of cancerassociated human mortalities [2, 3]. The prognosis of advanced, recurrent and metastatic GC is far from satisfactory. Current treatment options for this devastating disease are extremely limited [2, 3]. Molecularly-targeted therapies are the research focus for better GC therapies [4, 5]. Identification of novel therapeutic targets and biomarkers of GC is extremely urgent [4, 5]

Methods
Results
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.